- Home
- PSBD vs KRRO Comparison
PSBD vs KRRO Comparison
Compare PSBD & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- KRRO
- Stock Information
- Founded
- PSBD 2009
- KRRO 2014
- Country
- PSBD United States
- KRRO United States
- Employees
- PSBD N/A
- KRRO N/A
- Industry
- PSBD
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- KRRO Health Care
- Exchange
- PSBD Nasdaq
- KRRO Nasdaq
- Market Cap
- PSBD 391.6M
- KRRO 358.3M
- IPO Year
- PSBD 2024
- KRRO 2019
- Fundamental
- Price
- PSBD $12.70
- KRRO $46.28
- Analyst Decision
- PSBD Hold
- KRRO Strong Buy
- Analyst Count
- PSBD 5
- KRRO 7
- Target Price
- PSBD $13.80
- KRRO $96.71
- AVG Volume (30 Days)
- PSBD 123.9K
- KRRO 293.5K
- Earning Date
- PSBD 11-05-2025
- KRRO 11-11-2025
- Dividend Yield
- PSBD 14.03%
- KRRO N/A
- EPS Growth
- PSBD N/A
- KRRO N/A
- EPS
- PSBD N/A
- KRRO N/A
- Revenue
- PSBD N/A
- KRRO $6,281,000.00
- Revenue This Year
- PSBD N/A
- KRRO $116.91
- Revenue Next Year
- PSBD N/A
- KRRO N/A
- P/E Ratio
- PSBD N/A
- KRRO N/A
- Revenue Growth
- PSBD N/A
- KRRO N/A
- 52 Week Low
- PSBD $11.51
- KRRO $10.29
- 52 Week High
- PSBD $16.30
- KRRO $85.00
- Technical
- Relative Strength Index (RSI)
- PSBD 47.25
- KRRO 58.50
- Support Level
- PSBD $12.11
- KRRO $41.25
- Resistance Level
- PSBD $12.97
- KRRO $55.89
- Average True Range (ATR)
- PSBD 0.40
- KRRO 6.04
- MACD
- PSBD 0.05
- KRRO -0.75
- Stochastic Oscillator
- PSBD 53.15
- KRRO 43.70
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.